[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-detail-334619-en":59,"doc-seo-334619-105":81},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":5,"data":60},{"doc_id":61,"user_id":62,"nickname":63,"user_avatar":64,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":66,"doc_content":67,"file_id":68,"file_url":69,"file_type":70,"file_size":71,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":72,"language":73,"language_code":74,"site_id":75,"html_lang":74,"table_of_contents":76,"faqs":77,"seo_title":78,"seo_description":66,"update_tm":79,"read_time":80,"preview_page_count":4},334619,34359740700684,"Finn","https://ap-avatar.wpscdn.com/avatar/1f400023980c374ae676?_k=1777273430885731487","CPA4 as a biomarker promotes the proliferation, migration and metastasis of clear cell renal cell carcinoma cells","Clear cell renal cell carcinoma (ccRCC) is a highly aggressive malignancy with limited therapeutic options for advanced disease, driving the need for biomarkers and actionable targets. Carboxypeptidase A4 (CPA4), a zinc-containing metallocarboxypeptidase implicated in multiple cancers, was evaluated for its role in ccRCC. Analysis using TCGA and GEO, followed by validation in 24 patient specimens, showed CPA4 overexpression in ccRCC, correlating with more severe TNM/pathologic/histologic features and poorer survival outcomes. Protein-protein interaction, enrichment, and immune-infiltration analyses suggested CPA4-linked pathways and tumour microenvironment immune responses, while cell functional experiments supported CPA4’s mechanistic promotion of ccRCC progression.","DOI: 10. 1111/jcmm.18165  \nOR I G I NAL ART I C L E  \nCPA4 as a biomarker promotes the proliferation, migration and metastasis of clear cell renal cell carcinoma cells  \nKongjia Wang1  | Yixin Ding2  | Yunbo Liu3 | Mingyu Ma1 | Ji Wang1 | Zengshun Kou1 | Shuo Liu1 | Bo Jiang1 | Sichuan Hou1  \n1Department of Urology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China  \n2Department of Oncology, The Affiliated Hospital of Qingdao University, Qingdao, China  \n3 Department of Urology, The Affiliated Hospital of Qingdao University, Qingdao, China  \nCorrespondence  \nBo Jiang and Sichuan Hou, Department of Urology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China. [Email:](Email: jiangboqdy@126.com)[ jiangboqdy@126.com](Email: jiangboqdy@126.com) and [housichuandoctor@126.com](housichuandoctor@126.com)  \nAbstract  \nClear cell renal cell carcinoma (ccRCC) is a commonly occurring and highly aggressive urological malignancy characterized by a significant mortality rate. Current therapeutic options for advanced ccRCC are limited, necessitating the discovery of novel biomarkers and therapeutic targets. Carboxypeptidase A4 (CPA4) is a zinccontaining metallocarboxypeptidase with implications in various cancer types, but its role in ccRCC remains unexplored. The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases were utilized in order to investigate the differential expression patterns of CPA4 . The expression of CPA4 in ccRCC patients was further verified using immunohistochemical (IHC) examination of 24 clinical specimens. A network of protein–protein interactions (PPI) was established, incorporating CPA4 and its genes that were expressed differentially. Functional enrichment analyses were conducted to anticipate the contribution of CPA4 in the development of ccRCC. To validate our earlier study, we conducted real-time PCR and cell functional tests on ccRCC cell lines. Our findings revealed that CPA4 is overexpressed in ccRCC, and the higher the expression of CPA4, the worse the clinical outcomes such as TNM stage, pathological stage, histological grade, etc. Moreover, patients with high CPA4 expression had worse overall survival, diseasespecific survival and progress-free interval than patients with low expression. The PPI network analysis highlighted potential interactions contributing to ccRCC progression. Functional enrichment analysis indicated the involvement of CPA4 in the regulation of key pathways associated with ccRCC development. Additionally, immune infiltration analysis suggested a potential link between CPA4 expression and immune response in the tumour microenvironment. Finally, cell functional studies in ccRCC cell lines shed light on the molecular mechanisms underlying the role of CPA4 in promoting ccRCC formation. Overall, our study unveils CPA4 as a promising biomarker with prognostic potential in ccRCC. The identified interactions and pathways provide valuable insights into its implications in ccRCC development and offer a foundation for future research on targeted therapies. Further investigation of CPA4's involvement in immune  \n\n| Bo Jiang and Sichuan Hou are co-corresponding authors. |\n| --- |\n| This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.\u003Cbr>© 2024 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd. |\n\nJ Cell Mol Med. 2024;28:e18165 .  \n[https://doi.org/10.1111/jcmm.18165](https://doi.org/10.1111/jcmm.18165)  \n[wileyonlinelibrary.com/journal/jcmm](wileyonlinelibrary.com/journal/jcmm)  \n1 of 15  \nresponses may contribute to the development of immunotherapeutic strategies forccRCC treatment.  \nK E Y WO R D S  \nbiomarkers, CPA4, kidney renal clear cell carcinoma, molecular mechanism, prognosis  \n1 | INTRODUCTION  \nRenal cell carcin","cbCaieGIKsX3WxwZ","https://ap.wps.com/l/cbCaieGIKsX3WxwZ","pdf",16158879,15,"English","en",105,"# Abstract\n# Introduction\n## Background on ccRCC\n## Rationale for studying CPA4 in ccRCC","[{\"question\":\"What is the main purpose of studying CPA4 in clear cell renal cell carcinoma (ccRCC)?\",\"answer\":\"To determine whether CPA4 functions as a biomarker and contributes to ccRCC development, including prognosis and underlying molecular mechanisms.\"},{\"question\":\"How was CPA4 expression evaluated in ccRCC patients?\",\"answer\":\"CPA4 differential expression was analyzed using TCGA and GEO, then verified with immunohistochemical staining of 24 clinical specimens, supported by molecular and cell functional tests.\"},{\"question\":\"What relationship does CPA4 have with clinical outcomes and tumor progression?\",\"answer\":\"Higher CPA4 expression is associated with worse TNM and pathological/histological features and poorer overall and disease-specific survival, as well as a shorter progress-free interval.\"}]","CPA4 as a biomarker promotes the proliferation, migration and metastasis of clear cell renal cell carcinoma cells | PDF",1790007502,38,{"code":4,"msg":82,"data":83},"ok",{"site_id":75,"language":74,"slug":84,"title":65,"keywords":85,"description":66,"schema_data":86,"social_meta":140,"head_meta":142,"extra_data":144,"updated_unix":145},"cpa4-as-a-biomarker-promotes-the-proliferation-migration-and-metastasis-of-clear-cell-renal-cell-carcinoma-cells","",{"@graph":87,"@context":139},[88,102,122],{"@type":89,"itemListElement":90},"BreadcrumbList",[91,95,97,100],{"item":92,"name":93,"@type":94,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":96,"name":9,"@type":94,"position":14},"https://docshare.wps.com/document/",{"item":98,"name":40,"@type":94,"position":99},"https://docshare.wps.com/document/research-report/",3,{"item":101,"name":65,"@type":94,"position":19},"https://docshare.wps.com/document/cpa4-as-a-biomarker-promotes-the-proliferation-migration-and-metastasis-of-clear-cell-renal-cell-carcinoma-cells/334619/",{"url":101,"name":65,"@type":103,"image":104,"author":109,"headline":65,"publisher":111,"fileFormat":114,"inLanguage":74,"description":66,"dateModified":115,"datePublished":116,"encodingFormat":114,"isAccessibleForFree":117,"interactionStatistic":118},"DigitalDocument",{"url":105,"@type":106,"width":107,"height":108},"https://docshare.wps.com/thumbnails/cpa4-as-a-biomarker-promotes-the-proliferation-migration-and-metastasis-of-clear-cell-renal-cell-carcinoma-cells/334619.png","ImageObject",300,407,{"name":63,"@type":110},"Person",{"url":92,"name":112,"@type":113},"DocShare","Organization","application/pdf","2026-11-01","2026-09-21",true,{"@type":119,"interactionType":120,"userInteractionCount":39},"InteractionCounter",{"@type":121},"ViewAction",{"@type":123,"mainEntity":124},"FAQPage",[125,131,135],{"name":126,"@type":127,"acceptedAnswer":128},"What is the main purpose of studying CPA4 in clear cell renal cell carcinoma (ccRCC)?","Question",{"text":129,"@type":130},"To determine whether CPA4 functions as a biomarker and contributes to ccRCC development, including prognosis and underlying molecular mechanisms.","Answer",{"name":132,"@type":127,"acceptedAnswer":133},"How was CPA4 expression evaluated in ccRCC patients?",{"text":134,"@type":130},"CPA4 differential expression was analyzed using TCGA and GEO, then verified with immunohistochemical staining of 24 clinical specimens, supported by molecular and cell functional tests.",{"name":136,"@type":127,"acceptedAnswer":137},"What relationship does CPA4 have with clinical outcomes and tumor progression?",{"text":138,"@type":130},"Higher CPA4 expression is associated with worse TNM and pathological/histological features and poorer overall and disease-specific survival, as well as a shorter progress-free interval.","https://schema.org",{"og:url":101,"og:type":141,"og:title":65,"og:site_name":112,"og:description":66},"article",{"robots":143,"canonical":101},"index,follow",{"doc_id":61,"site_id":75},1790911533]